Remodeling Atrial Conduction and Hemodynamics with Bachmann Bundle Pacing in ICD Patients : A Prospective Single-Center Randomized Trail

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011800

Enrollment

Registered

2026-04-01

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : Experimental group: Bachmann’s bundle pacing ICD (BBP-ICD)/ Active comparator group: Conventional dual-chamber ICD with the atrial lead placed in the right atrial appendage (RAA) (

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who are >18 years old 2) planning to undergo implantation of Implantable Cardioverter-Defibrillator approved indication due to HFrEF (either primary prevention or secondary prevention) 3) Patients with double-chamber Implantable Cardioverter-Defibrillator insertion 4) Whether sinus dysfunction exists or not, atrial pacing would be activated regardless of the pacing ratio during resting time. 5)a patient who can submit written consent

Exclusion criteria

Exclusion criteria: 1)Patients with arrhythmia, such as persistent atrial fibrillation, at the time of the procedure 2)a patient unable to perform atrial pacing due to permanent atrial fibrillation 3)Patients with clear Cardiac Resynchronization Therapy indications 4)Patients with contraindication to Implantable Cardioverter-Defibrillator insertion 5)Patients who have active infections, life expectancy less than one year, or are unable to cooperate in research follow-up 6)Pregnant women, lactating women, and women of childbearing age

Design outcomes

Primary

Measure	Time frame
Subjective improvement of symptoms or discomfort during exercise or daily routine by patient-reported outcome;Improvement of cardiac function: NT-proBNP, LVEF and LVOT Vmax on echocardiography;Improvement of atrial parameters: LA volume, MV E/A, MV e/e, and so on’;Holter monitoring: AF burden or other arrhythmias;Improvement of exercise capacity test such as 6min-walk test (6MWT) or CPX;Changes in blood pressure and subsequent dose titration of heart failure medications	—

Measure

Time frame

Subjective improvement of symptoms or discomfort during exercise or daily routine by patient-reported outcome;Improvement of cardiac function: NT-proBNP, LVEF and LVOT Vmax on echocardiography;Improvement of atrial parameters: LA volume, MV E/A, MV e/e, and so on’;Holter monitoring: AF burden or other arrhythmias;Improvement of exercise capacity test such as 6min-walk test (6MWT) or CPX;Changes in blood pressure and subsequent dose titration of heart failure medications

—

Secondary

Measure	Time frame
All-cause mortality;History of hospitalization due to heart failure or related heart disease such as AF;LVAD or HTPL due to Heart failure aggravation	—

Countries

Korea, Republic of

Contacts

Public ContactYujin Jung

Keimyung University Dongsan Hospital

jinew326@naver.com+82-53-258-4628

Outcome results